Baird raised the firm’s price target on Labcorp to $261 from $258 and keeps an Outperform rating on the shares. The firm believes the Street is being overly punitive around a handful of modest issues, which are largely transitory or sentiment based, while not reasonably considering 2025+ potential or favorable risk/reward at current low valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp Q2 2024 Financial Results and Conference Call Announcement
- Labcorp launches Global Trial Connect to accelerate clinical trials
- Laboratory Holdings Executives Present at Growth Stock Conference
- Labcorp announces new strategic service offerings
- Labcorp price target lowered to $243 from $261 at JPMorgan